Prognia
Drug Database
🇪🇺EU · EMARevokedATC: L04AX07

Dimethyl fumarate Neuraxpharm(dimethyl fumarate)

Multiple Sclerosis, Relapsing-Remitting

Marketing Authorisation Holder: Laboratorios Lesvi S.L.

EMA Authorisation: 13/05/2022

INN: dimethyl fumarate

Indication

Dimethyl fumarate Neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Dimethyl fumarate Neuraxpharm — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.